Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
Fajri Gafar,Roeland E Wasmann,Helen M McIlleron,Rob E Aarnoutse,H Simon Schaaf,Ben J Marais,Dipti Agarwal,Sampson Antwi,Nguyen D Bang,Adrie Bekker,David J Bell,Chishala Chabala,Louise Choo,Geraint R Davies,Jeremy N Day,Rajeshwar Dayal,Paolo Denti,Peter R Donald,Ephrem Engidawork,Anthony J Garcia-Prats,Diana Gibb,Stephen M Graham,Anneke C Hesseling,Scott K Heysell,Misgana I Idris,Sushil K Kabra,Aarti Kinikar,Agibothu K Hemanth Kumar,Awewura Kwara,Rakesh Lodha,Cecile Magis-Escurra,Nilza Martinez,Binu S Mathew,Vidya Mave,Estomih Mduma,Rachel Mlotha-Mitole,Stellah G Mpagama,Aparna Mukherjee,Heda M Nataprawira,Charles A Peloquin,Thomas Pouplin,Geetha Ramachandran,Jaya Ranjalkar,Vandana Roy,Rovina Ruslami,Ira Shah,Yatish Singh,Marieke G G Sturkenboom,Elin M Svensson,Soumya Swaminathan,Urmila Thatte,Stephanie Thee,Tania A Thomas,Tjokosela Tikiso,Daan J Touw,Anna Turkova,Thirumurthy Velpandian,Lilly M Verhagen,Jana L Winckler,Hongmei Yang,Vycke Yunivita,Katja Taxis,Jasper Stevens,Jan-Willem C Alffenaar,Global Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in Pharmacokinetics of Anti-TB Drugs
DOI: https://doi.org/10.1183/13993003.01596-2022
2023-03-09
Abstract:Background: Suboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents at a global level. Methods: We systematically searched MEDLINE, Embase and Web of Science (1990-2021) for pharmacokinetic studies of first-line anti-TB drugs in children and adolescents. Individual patient data were obtained from authors of eligible studies. Summary estimates of total/extrapolated area under the plasma concentration-time curve from 0 to 24 h post-dose (AUC0-24) and peak plasma concentration (C max) were assessed with random-effects models, normalised with current World Health Organization-recommended paediatric doses. Determinants of AUC0-24 and C max were assessed with linear mixed-effects models. Results: Of 55 eligible studies, individual patient data were available for 39 (71%), including 1628 participants from 12 countries. Geometric means of steady-state AUC0-24 were summarised for isoniazid (18.7 (95% CI 15.5-22.6) h·mg·L-1), rifampicin (34.4 (95% CI 29.4-40.3) h·mg·L-1), pyrazinamide (375.0 (95% CI 339.9-413.7) h·mg·L-1) and ethambutol (8.0 (95% CI 6.4-10.0) h·mg·L-1). Our multivariate models indicated that younger age (especially <2 years) and HIV-positive status were associated with lower AUC0-24 for all first-line anti-TB drugs, while severe malnutrition was associated with lower AUC0-24 for isoniazid and pyrazinamide. N-acetyltransferase 2 rapid acetylators had lower isoniazid AUC0-24 and slow acetylators had higher isoniazid AUC0-24 than intermediate acetylators. Determinants of C max were generally similar to those for AUC0-24. Conclusions: This study provides the most comprehensive estimates of plasma exposures to first-line anti-TB drugs in children and adolescents. Key determinants of drug exposures were identified. These may be relevant for population-specific dose adjustment or individualised therapeutic drug monitoring.